HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 20, Pages 5506-5516
Publisher
American Society of Hematology
Online
2011-07-20
DOI
10.1182/blood-2011-02-336891
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- von Hippel–Lindau protein promotes Skp2 destabilization on DNA damage
- (2011) J-S Roe et al. ONCOGENE
- Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma
- (2010) V. V. Leshchenko et al. BLOOD
- DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma
- (2010) R. Shaknovich et al. BLOOD
- Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies
- (2010) E. Marchi et al. CLINICAL CANCER RESEARCH
- Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
- (2010) Frederick Lansigan et al. DRUGS
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
- (2010) Cliona Grant et al. Expert Review of Anticancer Therapy
- Therapy with azanucleosides for myelodysplastic syndromes
- (2010) Alfonso Quintás-Cardama et al. Nature Reviews Clinical Oncology
- Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia
- (2009) M. Kanduri et al. BLOOD
- Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
- (2009) M. T. Voso et al. CLINICAL CANCER RESEARCH
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- Current status of epigenetic treatment in myelodysplastic syndromes
- (2008) Andrea Kuendgen et al. ANNALS OF HEMATOLOGY
- Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
- (2008) M. Crump et al. ANNALS OF ONCOLOGY
- Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas
- (2008) K. Amara et al. ANNALS OF ONCOLOGY
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
- (2008) L. Paoluzzi et al. BLOOD
- Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-κB pathway as a target for new therapeutic strategies
- (2008) Alessandro Pavan et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started